TrialLeukemia research2021

Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial.

Selina M Luger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.